|Bid||130.83 x 800|
|Ask||130.91 x 1100|
|Day's Range||129.38 - 132.25|
|52 Week Range||101.42 - 142.50|
|Beta (3Y Monthly)||0.89|
|PE Ratio (TTM)||31.74|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Varian Medical Systems Inc NYSE:VARView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for VAR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting VAR. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $790 million over the last one-month into ETFs that hold VAR are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! As Varian Medical Systems, Inc. (NYSE:VAR) announced its earnings release on 29 March 2019...
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on April ...
Boston Scientific (BSX) is investing in new technologies and the global markets, which in turn, aids the uptick in sales across its most geographies in Q1.
Higher revenues, solid segmental performance and strong adjusted gross margins benefit Merit Medical's (MMSI) Q1 earnings. However, higher expenses remain a concern.
Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q1 earnings.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics ...
This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.
Varian (VAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Driven by Medidata's (MDSO) standardized clinical data storehouse, and operating on its pioneering platform, Acorn AI is set to become one of the premier AI companies in the field of life sciences.
To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. We'll use ROE to examine Varian Medical Systems...